PMID int64 35.7M 36.4M | Title/Abstract stringlengths 22 8.78k | MeshTerms stringlengths 7 101 | SemanticTypes stringlengths 4 64 |
|---|---|---|---|
36,263,095 | applic ct multimod imag rehabilit monitor long distanc run order monitor rehabilit athlet injur long distanc run author propos method rehabilit monitor long distanc run base ct multimod imag method combin latest multimod imag technolog integr multimod technolog ct imag improv accuraci perform imag segment ct multimod imag medic segment method analyz segment imag final achiev effect rehabilit treatment athlet long distanc run experiment result show total time taken author method hour averag time second much shorter two control method conclus author method allow better rehabilit monitor long distanc run sport injuri | D014057;D012420 | T060;T056 |
36,263,059 | defici mst endometriosi relat periton macrophag promot autophagi ectop endometri stromal cell il chang function periton macrophag contribut homeostasi periton immun microenviron endometriosi mechan ectop tissu escap phagocyt clearanc macrophag achiev ectop colon prolifer unknown express cd periton macrophag patient endometriosi increas overexpress mapk promot type polar macrophag reduc abil phagocytos ectop endometri cell upstream regul mapk mst express defici periton macrophag patient endometriosi process regul mir p noncod rna target mst moreov mst knockout macrophag secret anti inflammatori factor il promot autophagi ectop endometri stromal cell result suggest mst defici macrophag may acceler autophagi ectop endometrium via il regul mir p | D004715;D035683;D017346 | T123;T116;T191;T126;T114;T047 |
36,263,058 | mis c covid sociat condit hypoimmun hyperimmun multisystem inflammatori syndrom children mis c rare sever complic covid better knowledg immunolog cellular genet characterist mis c could help better understand pathogenesi diseas contribut identifi specif diagnost biomark develop target therapi studi mis c children hospit admiss healthi control analyz serum cytokin ifn ifn ifn il il il il p tnf lymphocyt popul flow cytometri gene relat autoimmun diseas autoinflamm primari immunodefici ngs mis c patient show signific increas serum ifn despit signific reduct activ th il even great heterogen among patient reveal differ pathway involv mis c pathogenesi suggest serum cytokin admiss may help select inflammatori pathway target patient flow cytometri demonstr relev reduct popul percentag b cell increas agreement autoimmun pathogenesi mis c genet analysi identifi variant gene patient least one gene variant among mutat patient gene relat autoimmun diseas like atm ncf mcm fcn dock autoinflammatori diseas associ releas ifn like prf nod mef thus incomplet clearanc sar cov acut phase may induc tissu damag self antigen exposur genet variant predispos hyper reactiv immun dysregul event mis c syndrom type ii ifn activ cytokin respons main il il may caus cytokin storm patient sever acut phase diseas lymphopenia multisystem organ involv time identif patient immunocytometr panel might critic target therapeut manag | D000086382;D007153;D001327 | T047;T067 |
36,263,057 | cd control develop activ monocyt macrophag axi chronic schistosomiasi schistosomiasi neglect tropic diseas caus worm genus schistosoma spp progress diseas result intens tissu fibrosi high mortal rate egg deposit adult worm inflammatori respons character robust activ type immun monocyt macrophag play critic role schistosomiasi inflammatori lyc high monocyt recruit blood inflammatori foci differenti altern activ macrophag aam promot tissu repair common chain integrin cd regul monocytopoiesi mediat resist experiment schistosomiasi still limit knowledg mechan control cd impact monocyt develop effector cell macrophag schistosomiasi show cdlow mice chronic infect mansoni display monocyt progenitor reduc prolif capac result accumul progenitor cell denomin prolifer monocyt pmo consequ inflammatori lyc high patrol lyc low monocyt reduc bone marrow blood mechanist low cd express decreas irf gene express pmo progenitor cell whose encod transcript factor regul csfr cd express cell surfac furthermor low cd express affect accumul inflammatori lyc high cdb monocyt liver adopt transfer cell infect cdlow mice reduc inflammatori infiltr fibrosi liver import express il chill arg downregul cd pd l aam reduc lower level il liver cdlow mice chronic infect mansoni overal find suggest cd control irf cd axi pmo progenitor cell affect prolifer matur monocyt time cd crucial appropri polar function aam tissu repair chronic schistosomiasi | D012552;D018821 | T129;T047;T116;T192 |
36,263,056 | continu renal replac therapi attenu polymorphonuclear myeloid deriv suppressor cell expans pediatr sever sepsi myeloid deriv suppressor cell mdscs expans import mechan under immunosuppress sepsi though continu renal replac therapi crrt may attenu hyperinflammatori respons sepsi role regul mdscs unknown aim studi assess potenti role crrt involv sepsi induc mdscs expans pediatr sepsi | D000072737;D000079664;D018805 | T061;T047;T046;T025 |
36,263,055 | sar cov specif igg iga respons matern blood breastmilk vaccin nave convalesc lactat particip recent studi shown presenc sar cov specif antibodi milk breastfeed mother vaccin mrna convalesc howev limit inform avail lactat women receiv vaccin platform use develop countri inactiv sar cov vaccin bbibp corv sinopharm non replic adenovirus vaccin sputnik v gamaleya institut chadox oxford astrazeneca | D062705;D014765;D000086382 | T129;T121;T116;T067;T047 |
36,263,054 | impact natur killer cell outcom allogen hematopoiet stem cell transplant systemat review meta analysi natur killer nk cell play vital role earli immun reconstitut follow allogen hematopoiet stem cell transplant hsct | D006086;D018380 | T061;T047 |
36,263,053 | helminth infect helminth deriv product novel therapeut option non alcohol fatti liver diseas non alcohol fatti liver diseas nafld close relat obes diabet metabol syndrom met becom common chronic liver diseas helminth co evolv human induc multipl immunomodulatori mechan modul host immun system use immunomodulatori abil helminth product exhibit protect various autoimmun inflammatori diseas includ obes diabet met close associ nafld review pathogenesi nafld abnorm glycolipid metabol inflamm gut dysbiosi correspond helminth product treat reliev nafld relat diseas includ obes diabet met promot glycolipid metabol homeostasi regul inflamm restor balanc gut microbiota consid larg number clinic trial carri helminth product treatment inflammatori diseas promis result treatment nafld obes relat diseas helminth also novel direct strategi | D065626;D024821;D006376;D006373 | T047;T204 |
36,263,052 | white blood cell count mean platelet volum ratio ischem stroke patient intraven thrombolysi white blood cell count mean platelet volum ratio wmr increas recogn promis biomark howev predict capabl acut ischem stroke ai patient relat less research primari aim studi explor prognost valu ai patient reperfus regard month poor function outcom | D002545;D000083242;D020521 | T047;T046 |
36,263,051 | atopi independ predictor long term patient graft surviv kidney transplant atopi genet condit predispos individu develop immunoglobulin e ige common allergen helper th polar mechan impact atopi graft surviv solid organ transplant unknown | D006085;D016030 | T061;T042 |
36,263,050 | mir p protect osteoarthr inhibit subchondr angiogenesi target express tgfbr id excess subchondr angiogenesi key patholog featur osteoarthr oa alter balanc subchondr bone remodel caus progress cartilag degrad previous found mir p correl negat angiogenesi though specif mechan mir p relat angiogenesi subchondr bone oa progress remain unclear studi conduct identifi mir p modul subchondr angiogenesi mechan oa investig therapeut effect found mir p express correl negat subchondr endomucin posit emcn vasculatur knee joint oa mice mir p overexpress regul angiogen abil endotheli cell ec hypox condit vitro mechanist mir p inhibit ec angiogenesi suppress transform growth factor beta receptor tgfbr mrna translat degrad dna bind inhibitor id mrna addit tgfbr downregul express id reduc id level led negat feedback regul tgfbr enhanc inhibitori effect mir p angiogenesi oa mice mir p overexpress ec via adeno associ virus aav allevi cartilag degrad suppress type immun respons reliev symptom attenu subchondr emcn vasculatur subchondr bone remodel conclus identifi mir ptgfbrid axi subchondr ec modul oa progress via subchondr angiogenesi repres potenti oa therapi target | D035683;D010003;D000077293;D051796 | T123;T116;T192;T114;T047 |
36,263,048 | natur killer cell relat prognosi signatur character immun landscap predict prognosi hnscc head neck squamous cell carcinoma hnscc common head neck cancer high aggress heterogen result variabl prognos immunotherapeut outcom natur killer nk cell play essenti role malign develop diagnosi prognosi purpos studi establish reliabl signatur base gene relat nk cell nrgs thus provid new perspect assess immunotherapi respons prognosi hnscc patient | D006258 | T191 |
36,263,047 | tristetraprolin limit age relat expans myeloid deriv suppressor cell age result enhanc myelopoiesi associ increas preval myeloid leukemia product myeloid deriv suppressor cell mdscs tristetraprolin ttp rna bind protein regul immun relat cytokin chemokin destabil target mrnas ttp express known decreas age myeloid cell use ttp defici ttpko mice model age mice studi ttp regul age relat myelopoiesi ttpko myeloid specif ttpko cttpko mice signific increas mdsc subpopul mdscs cdb lyc hi lyg pmn mdscs cdb lyc lo lyg well macrophag cdb f spleen mesenter lymph node howev quantit chang mdscs observ bone marrow contrast gain function ttp knock ttpki mice chang mdscs compar control mice within bone marrow total granulocyt monocyt progenitor gmps monocyt progenitor mps direct anteced mdscs signific increas cttpko ttpko mice granulocyt progenitor gps signific increas ttpko mice transcriptom analysi bone marrow myeloid cell popul reveal express cc chemokin receptor ccr play key role monocyt mobil inflammatori site dramat increas cttpko ttpko mice concurr concentr cc chemokin ligand ccl major ligand ccr high serum cttpko ttpko mice suggest ttp impact mobil mdscs bone marrow inflammatori site age via regul ccr ccl axi collect studi demonstr previous unrecogn role ttp regul age associ myelopoiesi expans specif myeloid progenitor mdscs recruit site injuri inflamm patholog perturb | D000072737 | T025 |
36,263,045 | decoupl blood telomer length age recipi allogen hematopoiet cell transplant bmt ctn age allogen hematopoiet cell transplant hct donor hematopoiet cell telomer length tl might affect recipi outcom goal examin possibl effect donor factor recipi hematopoiet cell tl quantifi hematopoiet cell tl shorten critic first three month post hct measur hematopoiet cell tl paramet recipi donor pair blood marrow transplant clinic trial network protocol southern blot sb telomer shortest length assay tesla quantit pcr qpcr recipi hematopoiet cell tl paramet post hct correl donor age p method recipi age donor pre hct hematopoiet cell tl p fold annual tl shorten adult p qpcr detect shorten recipi tesla detect buildup post hct telomer kb recipi p conclus hct decoupl hematopoiet cell tl recipi age reflect donor age potenti donor age effect outcom hct might partial mediat short hematopoiet cell tl older donor qpcr base tl measur suboptim detect telomer shorten post hct | D018380;D019737 | T061;T023;T025;T024 |
36,263,044 | cell defici hyperinflammatori monocyt respons associ mycobacterium avium complex lung diseas immunolog mechan suscept nontubercul mycobacteri ntm diseas poor understood understand ntm pathogenesi evalu innat antigen specif adapt immun respons mycobacterium avium complex mac asymptomat individu previous histori mac lung diseas macdz hypothes mav specif immun respons associ suscept mac lung diseas measur mac ntm macmtb specif cell respons cytokin product express surfac marker analysi global gene express macdz individu healthi control also analyz global gene express mycobacterium avium infect uninfect peripher blood monocyt macdz healthi control unabl detect increas cell respons mac specif reagent macdz compar control respons non mycobacteria deriv antigen preserv macdz individu lower frequenc th th cell popul addit macdz subject lower transcript respons pbmcs stimul mycobacteri peptid pool mtb contrast global gene express analysi demonstr upregul proinflammatori pathway uninfect avium infect monocyt ie hyperinflammatori vitro respons deriv macdz subject compar control togeth data suggest novel immunolog defect under mac pathogenesi includ concurr innat adapt dysregul persist year complet treatment | D015270;D008171 | T047 |
36,263,043 | multi facet approach sex gender equiti solid organ transplant women transplant initi transplant societi advanc women career transplant continu challeng academ career basic clinic disciplin transplant surgeri manag end organ failur medic specialti underrepres divers gender ethnic last decad women transplant initi wit solidifi becom intern recogn organ activ focus divers inclus term sex wit organ divid pillar address career advanc network pillar scientif investig present sex gender transplant pillar investig facilit equit access transplant women throughout world pillar take multiprong approach collabor across contin leverag virtual platform inform dissemin discuss provid financi support research wit becom high visibl grass root organ aim improv experi women transplant profession well transplant donor recipi | D000084803;D016377 | T078;T061 |
36,263,042 | comprehens analysi clinic signific immun infiltr biolog role march ligas hcc membran associ ring ch march famili member e ubiquitin ligas confirm grow number studi associ immun function highlight potenti immunotherapi target research hepatocellular carcinoma hcc patient divid c c march ligas relat pattern non negat matrix factor nmf algorithm multipl analys reveal march ligas relat cluster relat prognosi clinicopatholog characterist tumor immun microenviron time next signatur risk score march prognosi construct includ eight gene associ march ligas cypc gpd slca spp anxa cdc pon ftcd risk score show accuraci stabil found correl risk score time tumor mutat burden tmb prognosi clinicopatholog characterist signific addit risk score also import guid signific hcc treatment includ chemotherapi immunotherapi transarteri chemoembol tace | D006528;D016461;D008113 | T061;T191 |
36,263,041 | case report ruxolitinib first line therapi secondari hemophagocyt lymphohistiocytosi patient aid hemophagocyt lymphohistiocytosi hlh fatal immunolog syndrom result excess product inflammatori cytokin convent therapi hlh base cytotox agent alway efficaci safe especi patient sever immunodefici ruxolitinib strong inhibitor janus kinas jak alreadi evalu salvag first line therapi hlh despit promis efficaci toler treatment secondari hlh efficaci safeti ruxolitinib hlh patient hiv infect remain investig | D051359;D015658;D000163 | T047 |
36,263,040 | singl center blind test us multi center valid diagnost algorithm kawasaki diseas taiwan kawasaki diseas kd lead caus acquir heart diseas children major challeng kd diagnosi share clinic sign childhood febril control fc subject sought determin algorithm approach appli taiwan cohort | D009080 | T047 |
36,263,039 | fluorin label therapeut human tolerogen dendrit cell f magnet reson imag tolerogen dendrit cell toldc therapi aim restor self toler patient suffer autoimmun diseas phase clinic trial toldc shown feasibl safeti approach also highlight lack understand distribut vivo fluorin magnet reson imag f mri promis attract cell track method allow detect f label cell non invas longitudin manner test suitabl nanoparticl contain f f np label therapeut human toldc detect f mri found toldc readili endocytos f np accept effect cell viabil yield mri signal nois ratio obtain suffici detect administ toldc dose million cell inject site vivo depend tissu depth rate cell dispers import f np label revert toldc immunogen dc confirm low express typic matur dc surfac marker cd cd low secret pro inflammatori il p low capac induc ifn allogen cd cell addit capac toldc secret anti inflammatori il diminish f np label conclud f np suitabl imag agent toldc current avail technolog imag approach yet approach sensit requir detect small number migrat cell could import util determin accuraci inject toldc desir target tissu efflux rate | D005461;D007108 | T040;T123;T196;T046 |
36,263,038 | distinct respons newli identifi monocyt subset advanc gastrointestin cancer covid monocyt critic cell immun system role effector relat poor understood long consid precursor tissu macrophag dendrit cell moreov known cell type heterogen understand aspect limit broad classif classicalintermediatenon classic monocyt common base express two marker ie cd cd deepli dissect heterogen human circul monocyt healthi donor transcriptom analysi singl cell level identifi distinct monocyt popul character profil suggest special function classic monocyt subset fact includ five distinct popul enrich transcriptom gene set relat either inflammatori neutrophil like interferon relat platelet relat pathway non classic monocyt includ two distinct popul one mark specif elev express level complement compon intermedi monocyt divid analysi character high level human leukocyt antigen hla gene final identifi one cluster includ classic non classic monocyt character strong cytotox signatur find provid rational exploit relev newli identifi monocyt popul diseas evolut machin learn approach develop appli two singl cell transcriptom public dataset gastrointestin cancer coronavirus diseas covid patient dissect dataset classif reveal patient advanc cancer show select increas monocyt enrich platelet relat pathway note signatur associ popul correl wors prognosi gastric cancer patient convers immunotherapi activ popul compos interferon relat monocyt consist upregul interferon relat gene respond patient compar non respond covid patient confirm global activ phenotyp entir monocyt compart classif reveal cytotox monocyt expand diseas progress collect studi unravel unexpect complex among human circul monocyt highlight exist special popul differ engag depend patholog context | D000086382;D005770 | T047;T191;T067 |
36,263,037 | probiot multifacet oral vaccin colon cancer review probiot known live microorgan upon adequ administr elicit health benefici respons insid host probiot known immunomodul exhibit anti tumor properti advanc research explor potenti use probiot oral vaccin without latent risk pathogen probiot base oral vaccin known induc mucos immun prevent host sever enter infect probiot bacteria abil produc metabolit form anti inflammatori cytokin play import role prevent carcinogenesi activ phagocyt elimin preliminari stage cancer cell review discuss advantag disadvantag use oral probiot vaccin well mechan action probiot colon cancer therapi review also employ use probio databas select certain probiot immunomodulatori properti furthermor use sever probiot bacteria anti colon cancer adjuv also discuss detail current studi trial focus use attenu pathogen instead use probiot base vaccin futur studi must involv advanc research exploit potenti sever probiot strain adjuv cancer therapi | D019936;D014612;D009369 | T121;T129;T007;T116;T191 |
36,263,036 | pd pd l combin lag associ clinic activ immun checkpoint inhibitor metastat primari pulmonari lymphoepithelioma like carcinoma primari pulmonari lymphoepithelioma like carcinoma plelc epstein barr virus ebv relat rare subtyp non small cell lung cancer nsclc immun checkpoint inhibitor ici show durabl respons advanc nsclc howev effect predict biomark plelc remain poor understood retrospect analyz data metastat plelc patient treat ici pretreat paraffin embed specimen n stain pd pd l lag tim cd cd cd cd foxp cytokeratin ck multipl immunohistochemistri mihc next generat sequenc perform plelc sampl among patient treat ici monotherapi n object respons rate orr diseas control rate dcr median progress free surviv mpfs overal surviv mos month month respect patient pd l show longer pfs vs month p relat pd l among patient treat ici combin therapi n orr dcr mpfs mos month month respect patient pd l show signific superior os pd l na versus month p among mihc patient high pd pd l lag express show longer pfs vs month p ici also show promis efficaci treat metastat plelc pd l may predict ici treatment efficaci prognost surviv plelc pd pd l combin lag may serv predictor ici treatment effect plelc larger prospect trial warrant valid ici activ predict biomark plelc studi part present poster iaslc th world confer lung cancer septemb barcelona spain | D002289;D008175;D000074322;D020031;D002294 | T121;T129;T116;T191;T047 |
36,263,035 | random clinic trial stimul cholinerg anti inflammatori pathway patient moder covid pneumonia use slow pace breath techniqu characterist problem occur covid excess elev pro inflammatori cytokin eg il crp associ wors clinic outcom stimul vagal mediat cholinerg anti inflammatori reflex slow pace breath prolong exhal may present clinic relev way reduc circul il | D000086382 | T047;T067 |
36,263,034 | live mucos vaccin stimul potent protect via vari cd cd cell subset wild type brucella melitensi challeng emerg zoonot pathogen brucella spp continu impact develop countri persist expand popul wildlif speci us constant threaten infect domest herd develop improv anim human vaccin remain prioriti studi immun novel live attenu b melitensi strain term znbm mc character oral prime intranas boost strategi confer exquisit protect pulmonari challeng wild type wt b melitensi provid near complet protect lung spleen brucella colon vaccin znbm mc show ifn cd cell bias lung oppos rev vaccin mice show ifn cd cell inclin lung cd cd effector memori cell tem increas fold lung cd cd resid memori cell trms increas fold respect cell serv primari produc ifn lung essenti vaccin clearanc predomin cytokin generat pre post challeng wt b melitensi znbm mc growth could arrest ifn mice increas lung tnf il also induc il most deriv cd cell vaccin cd cd b mice znbm mc confer full protect lung spleen post pulmonari challeng virul b melitensi vaccin il mice result protect lung spleen data demonstr efficaci mucos vaccin administr generat protect memori cell wt b melitensi | D017347;D002004;D002006 | T121;T129;T047;T007 |
36,263,033 | emerg role il il colorect cancer tumorigenesi colorect cancer crc second lead caus cancer relat death worldwid larg refractori current immunotherapeut intervent lack efficaci exist cancer immunotherapi crc reflect complex natur uniqu intestin immun environ serv maintain barrier integr pathogen harm environment stimuli sustain host microb symbiosi homeostasi express barrier epitheli cell cytokin interleukin il il play key role intestin immun respons associ inappropri allerg reaction autoimmun diseas cancer patholog studi past decad begun uncov import role il il shape crc tumour immun microenviron may promot inhibit tumorigenesi depend specif crc subtyp notabl il il shown act group innat lymphoid cell ilc also stimul array innat adapt immun cell type though sometim function overlap also produc distinct phenotyp depend differenti distribut receptor express furthermor il il modul pathway previous known contribut crc tumorigenesi includ angiogenesi tumour stem invas metastasi review current understand il il crc tumorigenesi specif focus dissect individu function context distinct subtyp crc potenti prospect target pathway crc immunotherapi | D000067596;D015179 | T129;T191;T116 |
36,263,032 | dynam chang metabolit kynurenin pathway alzheim diseas parkinson diseas huntington diseas systemat review meta analysi tryptophan trp essenti amino acid must provid diet kynurenin pathway kp main rout trp catabol nicotinamid adenosin dinucleotid nad metabolit pathway may protect degen effect nervous system thus kp may involv neurodegen diseas | D000544;D010300;D006816 | T047;T048 |
36,263,031 | vaccin model predict rule updat vaccin evolv pathogen sar cov influenza context pre exist immun current vaccin sar cov influenza virus updat new vaccin induc higher antibodi titer circul variant current vaccin approach account complex dynam prior immun skew recal respons updat vaccin use comput model mechanist dissect prior immun influenc recal respons ii explor affect rule evalu deploy updat vaccin iii appli sar cov analysi exist data suggest strong benefit updat current sar cov vaccin match current circul variant propos general two dose strategi determin vaccin need updat well vaccin high risk individu final direct valid model reanalysi earlier human hn influenza vaccin studi | D007252;D007251;D053124;D000086382 | T129;T121;T067;T109;T005;T047 |
36,263,030 | fast track develop vaccin sar cov shot save world decemb outbreak emerg sever acut respiratori syndrom coronavirus sar cov lead coronavirus diseas covid world health organis announc outbreak global health emerg januari march declar pandem spread sever outbreak took heavi toll overburden global health system particular sinc avail drug sar cov immedi worldwid effort communic share data larg amount fund research pharmaceut compani immedi fast track vaccin develop order prevent sever diseas hospit death number vaccin quick approv emerg use worldwid vaccin rollout immedi put place howev due sever individu hesit vaccin mani poorer countri access vaccin multipl sar cov variant quick emerg distinct origin variant uncertainti relat effect various vaccin new variant well vaccin specif side effect remain concern despit uncertainti fast track vaccin approv manufactur larg scale effect distribut covid vaccin remain topmost prioriti around world unpreced effort made vaccin developersresearch well healthcar staff play major role distribut vaccin shot provid protect andor reduc diseas sever death even delta omicron variant fortun even becom infect vaccin appear protect major diseas hospitalis fatal covid herein analys ongo vaccin studi vaccin platform save mani death pandem | D000086402;D000086382 | T005;T067;T047 |
36,263,029 | iga vascul updat epidemiolog pathogenesi biomark immunoglobulin vascul igav former known henoch schnlein purpura common system vascul children character divers clinic manifest wide spectrum rang isol cutan vascul system involv incid igav geograph ethnic variabl preval autumn winter suggest drive role genet environment factor play diseas although igav certain degre natur remiss vari wide among individu patient suffer sever renal involv even progress end stage renal diseas pathogenesi complex fulli elucid format galactos defici iga gd iga relat immun complex play vital role promot occurr develop igav nephriti addit neutrophil activ stimul bind iga fc alpha receptor express surfac result system vascular inflamm tissu damag start epidemiolog characterist articl review role immunolog factor gd iga autoantibodi circul immun complex complement system cellular immun contribut environment genet factor pathogenesi igav conclud major biomark igav | D011695 | T047 |
36,263,028 | simultan genotyp human platelet antigen system hla hla b loci target next generat sequenc order treat alloimmun platelet transfus refractori ptr human leukocyt antigen hla type andor human platelet antigen hpa type match platelet donor patient usual use therefor genotyp hla hla b loci well hpa system donor patient great signific howev rare report genotyp hla hla b loci well hpa system time studi high throughput method simultan genotyp hla hla b loci well hpa genotyp develop rna captur probe panel design cover exon sequenc gpba gpbb itga cd itgb itgab gene hla hla b loci hla hla b hpa system genotyp use target next generat sequenc ngs method genotyp hla hla b loci well hpa assign base nucleotid polymorph site use ngs method unrel blood specimen success genotyp hpa system well hla hla b loci accuraci ngs method hpa hpa hpa hpa w hpa hpa w show polymorph frequenc allel respect thirti two singl nucleotid variant snvs detect snvs lead amino acid chang hla hla b common allel hla hla b loci target next generat sequenc method simultan genotyp hpa system hla hla b loci first establish could use creat databas hla type andor hpa type unrel donor | D016824 | T129;T109 |
36,263,027 | next generat l base hpv vaccin cross protect cutan papillomavirus infect tumor develop licens l vlp base immun high risk mucos human papillomavirus hpv type great success reduc anogenit cancer although limit cross protect hpv type cover vaccin util protect cutan hpv type contribut non melanoma skin cancer nmsc develop rather low next generat vaccin achiev broad cross protect immun high conserv sequenc l exploratori studi test two novel hpv vaccin candid hpv rg vlp cut panhpvax preclin natur infect model mastomi coucha immun either vaccin mock control mnpv l vlps anim experiment infect monitor besid vaccin specif seroconvers hpv l peptid anim also develop cross reactiv antibodi cutan mastomi natalensi papillomavirus mnpv l cross neutral mnpv pseudovirion vitro l base vaccin also confer vivo protect viral load pluck hair experiment infect lower compar mock vaccin control anim import format neutral antibodi whether direct l vlps l abl prevent skin tumor format even microscop sign mnpv infect skin first time studi show proof principl next generat l base vaccin even across differ pv genera infect anim model genuin pv provid fundament insight humor immun elicit l base vaccin pv induc skin tumor import implic design next generat hpv vaccin | D053918;D030361;D009856;D058425;D009369 | T129;T121;T123;T116;T191;T047 |
36,263,026 | detect anti desmoglein antibodi oral lichen planus know far oral lichen planus olp inflammatori diseas oral mucosa clinic two main subset describ name non eros eros olp non eros olp usual respons local therapi eros olp often refractori also system therapi extrem reduc qualiti life patient furthermor eros olp case differ autoantibodi detect includ anti desmoglein autoantibodi anti bullous pemphigoid autoantibodi howev potenti role still clear paper review literatur detect autoantibodi desmoglein main target antigen pemphigus vulgari patient olp summar recent insight topic | D017676;D010392 | T047 |
36,263,025 | matern fetal neonat outcom among pregnant women receiv covid vaccin preg co vax studi although european medicin agenc ema encourag coronavirus diseas covid vaccin pregnant women scientif evid support use covid vaccin pregnanc still limit | D000086382;D000022;D014612 | T129;T121;T116;T067;T033;T047;T046 |
36,263,023 | biomark mechan toler induct food allerg patient drive new therapeut approach immunotherapi food allerg patient effect induc desensit popul long term toler remain elus target challeng face field differenti immun marker impact immunotherapi critic biomark toler data recent clinic trial identifi sever biomark mechan achiev toler biomark includ younger age lower food specif ige lower food compon specif ige specif linear epitop profil subset food specif cd cell addit biomark investig relev toler induct includ tcr repertoir gastrointestin skin microbiom local tissu immun mini review highlight recent advanc understand biomark mechan toler induct food immunotherapi influenc clinic trial develop | D003888;D006967 | T061;T046 |
36,263,022 | engin red blood cell activ antigen carrier drive potent cell respons tumor regress mice activ cell respons essenti effect tumor clearanc howev induc target potent antigen present stimul cell respons remain challeng generat activ antigen carrier aac engin red blood cell rbcs encapsul relev tumor antigen adjuv polyinosin polycytidyl acid poli c use tumor specif cancer vaccin process method condit use creat aac promot phosphatidylserin exposur rbcs thus har natur process age rbc clearanc enabl target aac endogen profession antigen present cell apc without use chemic viral vector aac uptak antigen process present apc drive antigen specif activ cell mous vivo human vitro system promot polyfunct cd cell tumor model drive high level antigen specif cd cell infiltr tumor kill efficaci aac therapi enhanc combin chemotherapeut agent cisplatin summari find support aac potenti vector free immunotherapi strategi enabl potent antigen present cell stimul endogen apc broad therapeut potenti | D019496 | T129;T121;T116 |
36,263,021 | human mous model vivo evalu invari natur killer cell respons invari natur killer inkt cell mediat immun respons stimul glycolipid agonist present cdd extens studi synthet analogu galactosyl ceramid identifi numer exampl signific differ recognit specif glycolipid wild type mice versus human inkt cell clone pbmc sampl predict human inkt cell respons accur mous model deriv mous line compound genet modif use express human like inkt cell tcr along human cdd place endogen mous protein detail transcript phenotyp profil demonstr partial human mice develop expand popul cell recogn cdd present glycolipid antigen among subset character express chemokin receptor cxcr featur characterist authent inkt cell respons inkt cell activ glycolipid mice generat cytokin product vitro vivo show pattern fine specif close resembl cultur human inkt cell clone anti tumor respons variant galactosyl ceramid vki mice also correl potenc stimul human inkt cell genet modifi mous line provid practic model human present recognit inkt cell activ context normal function immun system may furnish valuabl opportun preclin evalu inkt cell base therapi | D005699;D055611 | T123;T025;T109 |
36,263,004 | prognost signatur gxylt correl immun infiltr bladder cancer gxylt glucosid xylosyltransferas known import gene regul classic notch signal involv progress human tumor howev correl gxylt express bladder cancer remain unclear | D001749 | T191 |
36,263,003 | analysi correl basic fibroblast growth factor serum patient diffus larg b cell lymphoma clinicopatholog efficaci intern prognost index correl basic fibroblast growth factor bfgf serum patient diffus larg b cell lymphoma dlbcl clinicopatholog efficaci intern prognost index ipi analyz dlbcl patient admit hospit treatment june june select dlbcl patient group healthi subject receiv physic examin hospit period select healthi control group serum bfgf level dlbcl group healthi control group observ treatment experiment result show serum bfgf express dlbcl patient decreas signific chemotherapi serum bfgf express dlbcl patient close relat treatment effect diseas progress tumor invas prognosi import clinic signific judg diseas treatment effect prognosi patient | D016222;D016403 | T123;T191;T116 |
36,263,002 | efficaci safeti remimazolam besyl combin alfentanil painless gastroscopi random singl blind parallel control studi efficaci advers reaction remimazolam besyl rb combin alfentanil patient painless gastroscopi remain unclear | D015760;D015742 | T121;T109 |
36,263,001 | practic effect action intervent strategi combin base surgic psycholog factor studi main analyz relat surgic psycholog factor caus chang thirst degre gastrointestin surgeri observ practic effect action intervent strategi combin two factor reduc postop thirst degre base clinic data patient underw gastrointestin tumor resect hospit januari januari retrospect analyz degre thirst evalu visual analogu scale vas subject divid three group mild group n moder group n sever group n psycholog surgic indic compar analyz result show thirst degre light comfort mouth studi group better control group h surgeri signific differ compar h surgeri thirst degre oral discomfort control group h surgeri signific higher studi group h surgeri suggest action research intervent strategi high practic effect effect reduc postop thirst oral discomfort | D013894 | T039 |
36,263,000 | deconstruct risk predict ischem cardiovascular cerebrovascular diseas base deep learn year widespread use comput technolog dramat increas electron medic data data driven approach medic data analysi emerg howev analysi medic data remain challeng due mix natur data incomplet mani record high level nois paper propos improv neural network dbn lstm combin deep belief network dbn long short term memori lstm network subset featur attribut process cfs ega use train optim select test number hidden layer perform upper dbn process train dbn lstm time valid set combin determin hyperparamet lstm construct dnn cnn long short term memori lstm network compar analysi dbn lstm use classif method compar averag final result two experi result show predict accuraci dbn lstm cardiovascular cerebrovascular diseas reach higher three tradit neural network | D000077321;D002561 | T047;T066 |
36,262,999 | influenc air pollut pulmonari diseas incid analyz base grey correl analysi air pollut primari health threat issu worldwid close concern respiratori diseas random survey report around million peopl die ambient household air pollut especi peopl suffer asthma chronic obstruct pulmonari diseas copd high affect air pollut air pollut compon induc asthma onset copd acut exacerb lead maxim mortal morbid rate therefor influenc air pollut copd examin continu minim mortal rate sever method present field investig relationship health pollut howev exist approach predict short term data difficulti comput time redund data larg data analysi data continu research introduc meta heurist optim grey correl analysi mh gca solv research difficulti correl analysi sever model identifi relationship pollut factor copd diseas method analysi particul matter pm air pollut relev copd lung cancer diseas grey analysi use uncertainti concept identifi particl influenc air pollut analysi cuttlefish optim algorithm appli select relev featur pollut list reduc comput time correl analysi rate introduc system evalu use air qualiti dataset copd dataset develop help matlab tool system increas influenc recognit accuraci mcc decreas error rate differ pollut | D000397;D000393;D029424;D001249 | T131;T047;T069;T080 |
36,262,998 | knockdown long noncod rna linc inhibit esophag cancer progress regul mir p esophag cancer preval digest system tumor due lack characterist symptom earli diagnosi confirm esophag cancer typic detect progress harm stage therefor critic investig molecular mechan govern format progress esophag cancer order identifi new treatment target esophag cancer earli detect | D062085;D004938;D035683 | T123;T191;T114 |
36,262,997 | classif drug resist analysi pathogen bacteria patient bacteri pneumonia emerg intens care unit studi aim compar identif effici metagenom next generat sequenc mngs tradit method detect pathogen patient sever bacteri pneumonia bp analyz drug resist common pathogen | D002438;D018410 | T047;T195;T109 |
36,262,996 | role medic iot base bone age determin diagnosi clinic treatment dwarfism diseas monitor current preval dwarfism children china larg percentag compar larg popul base increas influenc factor preval dwarfism increas howev lack awar dwarfism among parent lack depth analysi caus dwarfism low level treatment among doctor earli expert system knowledg base reli manual edit tradit semi intellig auxiliari diagnost system unabl perform diseas diagnosi clinic treatment monitor well mani studi turn combin iot bone age determin role diagnosi monitor clinic treatment dwarfism studi children short statur underw health checkup hospit enrol studi g p spectrum method use determin bone age enrol subject result obtain process bone age determin systemat analyz result show bone age measur techniqu suffici refer valu evalu qualiti diagnos diseas research develop techniqu great signific develop modern clinic medicin | D004392 | T019 |
36,262,995 | correl decomposit tcm syndrom type calcium phosphorus metabol mainten hemodialysi suffer aim reveal relationship tcm syndrom type calcium phosphorus metabol mainten hemodialysi mhd suffer suffer diagnos mhd admit suixi counti hospit anhui provinc select retrospect decomposit data tcm classif laboratori indic suffer collect experiment result indic calcium phosphorus metabol disord common mainten hemodialysi patient especi calcium phosphorus product blood phosphorus elev increas calcium phosphorus product close relat mortal calcif rate subcutan soft tissu provid refer diagnosi therapi abnorm calcium phosphorus metabol suffer worthi clinic applic | D002118;D002114 | T123;T121;T196;T047;T046 |
36,262,994 | optim applic inform visual design base imag symbol guidanc featur integr theori increas today busi reli data visual aid outcom direct link bulk earn due enorm volum speed accuraci requir data manag databas profession becom increas necessari aid effect visual data assum inform depict free ambigu visual approach develop howev rare occurr recent upsurg visual attempt convey sens unpredict come visual optim present novel cognit fuzzi logic base particl swarm optim cflpso optim data visual initi dataset gather imag well denois enhanc employ bilater three dimension fair median filter b fmf contrast illumin histogram equal cihe correspond princip compon analysi pca util featur extract stage extract featur enhanc data featur integr theori appli extract featur also fast rectangl pack algorithm appli data visual propos approach employ visual optim perform propos techniqu examin compar exist techniqu obtain propos techniqu greatest effect visual optim find depict util origin tool | D017143;D000465 | T170 |
36,262,993 | status quo occup ident nurs staff rehabilit depart relationship work stressor due continu progress social economi medic health technolog develop disciplin shown trend rapid develop current medic environ qualiti nurs servic constant promot nurs staff dedic work best abil meanwhil reward correspond happi joy work studi start perspect nurs manag psycholog basi investig occup ident work stress status nurs staff time data analyz relationship occup ident work pressur analyz articl provid certain theoret basi support decis make relev nurs manag also make effort improv profession ident work happi nurs staff studi survey rehabilit nurs nurs total occup stress score averag score point overal score profession ident averag score point belong medium level show occup pressur nurs paid attent relev manag two five dimens highest score occup social support occup self reflect negat correl found occup stress dimens occup ident dimens p | D009741;D000073397 | T033;T054;T097;T048 |
36,262,992 | chang short term heart rate variabl vertebr arteri magnet reson angiographi patient cervic vertigo cervic vertigo refer clinic syndrom sudden vertigo main symptom caus hemodynam disturb extracrani segment vertebr arteri va affect cervic vertebr lesion small differ puls interv patient continu sinus rhythm call heart rate variabl hrv heart rate variabl refer small rise fall instantan heart rate consecut beat one import physiolog indic cardiac function small chang success beat reflect inform heart use diagnos heart diseas paramet use identifi emot therefor possibl use characterist heart rate variabl find pattern high stress state use comput ecg signal describ high stress state sinc ecg signal univers object model practic conveni use describ stress state magnet reson angiographi mr angiographi mra noninvas vascular imag method requir intub contrast agent present wide use clinic practic order explor chang short term heart rate variabl vertebr arteri magnet reson angiographi mra patient cervic vertigo clinic signific paper introduc two basic analysi method heart rate variabl common use mra techniqu tof technolog analysi heart rate variabl patient cervic vertigo statist valu time spectrum domain paramet found lower experiment group control group mra show abnorm rate va pci group cervic vertigo group similar rmssd index male experiment group reach control group reach | D014711;D062645 | T061;T023 |
36,262,991 | clinic valu petct base big data colorect periton metastat cancer studi focus evalu clinic util pet ct imag periton metastas colorect cancer one hundr patient colorect periton metastas underw whole bodi pet ct imag januari decemb select experiment group healthi individu select control group suvmax two group patient respect differ statist signific suvmax auc auc serum afp cea ca ca respect conclus patient colorect periton metastat cancer underw petct examin follow imag examin confirm diagnosi analysi roc curv studi found periton suvmax diagnost index colorect periton metastat cancer sum sensit specif reach maximum | D010534;D015179 | T191 |
36,262,990 | clinic applic shock wave treatment avascular necrosi femor head earli middl stage order observ clinic efficaci shock wave treatment avascular necrosi femor head earli middl stage clinic applic method shock wave treatment avascular necrosi femor head earli middl stage propos method combin ct imag segment technolog segment hip joint imag therebi speed treatment speed achiev better treatment effect experiment result show ct imag segment take hour averag time second faster method shock wave effect treatment method earli avascular necrosi femor head method becom one main method clinic treatment kind diseas | D005271;D000074059 | T061;T047;T046 |
36,262,989 | applic grey relat entropi weight method drg perform evalu inpati depart object analyz perform indic hospit orthoped depart base drg tool evalu medic servic abil orthoped depart provid theoret basi hospit build perform manag evalu system | D007297;D003953 | T081;T170;T101 |
36,262,988 | clinic analysi fetal lung develop index pregnanc outcom pregnant women gestat diabet mellitus satisfactori blood glucos control explor regular fetal lung develop pregnant women gestat diabet mellitus gdm satisfactori blood glucos control clinic analysi pregnanc outcom | D016640 | T047 |
36,262,987 | effect teach back combin king interact standard mode life copd patient copd common clinic chronic airway inflammatori diseas occur most middl age older adult age incid copd increas year year onset age gradual becom younger | D011788;D029424 | T078;T047 |
36,262,986 | characterist scan brain structur function chang patient differ degre alzheim diseas case control studi structur magnet reson imag smri scan mr spectrum mrs neuropsycholog assess intracrani structur alzheim diseas ad patient differ degre earli middl late earli clinic featur imag featur neuropsycholog characterist patient ad analyz provid help earli diagnosi ad data mr scan brain bilater mrs scan hippocampus thyroid function laboratori indic neuropsycholog evalu analysi collect patient diagnos ad accord cdr patient divid earli ad group middl advanc ad group patient earli ad group patient middl advanc ad group retrospect studi conduct analyz general condit medial tempor lobe atrophi mta grade metabol chang bilater mrs hippocampus patient group mini mental state examin mmse activ daili live scale adl neuropsycholog assess result moreov compar analysi carri result show mta grade medial tempor atrophi increas progress sever diseas group statist test conduct reduct hippocamp volum two group p less therefor mta scale great valu diagnosi stage earli ad howev diagnosi earli ad treat mta visual evalu alon fals negat diagnosi judgment earli ad depend metabol chang hippocampus mrs mr scan intracrani structur like caus fals negat diagnosi therefor combin mrs analysi mr scan intracrani structur favor earli diagnosi treatment ad combin neuropsycholog assess ad patient stage effect great improv accuraci ad diagnosi earli stage | D000544 | T047;T048 |
36,262,985 | implement machin learn mechan recognis prostat cancer photoacoust signal biolog tissu may studi use photoacoust pa spectroscopi yield wealth physic chemic data howev realli challeng direct analys tissu lot data data mine techniqu get around issu order diagnos prostat cancer via pa spectrum assess work describ machin learn ml techniqu implement supervis classif unsupervis hierarch cluster collect pa signal preprocess use pwelch method featur extract use two method hierarch cluster correl assess extract featur classifi use four ml method name support vector machin svm nave bay nb decis tree c linear discrimin analysi lda furthermor compon alter throughout progress prostat cancer studi focus composit distribut collagen lipid haemoglobin diseas tissu compar normal tissu stronger correl various chemic compon ultrason power spectra suggest microstructur dispers tumour tissu uniform accuraci sever classifi use cancer tissu diagnosi greater four method effect benchmark medic method thus method show signific promis noninvas earli detect sever prostat cancer | D000069550;D011471 | T191;T066 |
36,262,984 | intellig algorithm base ultrasound imag evalu therapeut effect radiofrequ ablat liver tumor analysi risk factor postop infect research aim explor therapeut effect radiofrequ ablat rfa liver tumor investig postop infect factor specif patient liver tumor undergo ultrasound guid fra select research subject diagnos hospit intellig fit algorithm compar genet algorithm ga appli rfa patient found run time algorithm time ga demonstr better global search capabl mean diamet singl liver tumor cm complet ablat rate tumor diamet less cm tumor diamet cm tumor diamet cm posttreat ast level decreas signific alb level increas signific differ notabl p p tbil level umol lower prior treatment umol alt level gl lower prior treatment gl show notabl differ p p diamet whether great vessel invas tnm stage associ infect rfa differ notabl ultrasound imag effect evalu therapeut effect rfa degre inactiv liver tumor addit tumor stage independ risk factor postop infect | D008113;D000078703;D017115 | T061;T191 |
36,262,983 | effect stress osteoblast prolifer differenti base endoplasm reticulum stress wnt catenin signal pathway order investig effect fluid shear stress prolifer osteoblast regulatori role wnt catenin signal pathway cell prolifer new method base endoplasm reticulum stress wnt catenin signal pathway stress mediat propos take mg osteoblast research object inocul glass slide g group polish titanium sheet p group sandblast acid base treat pure titanium sheet group addit fss dunescm static group dunescm stress group given respect quantit revers transcript pcr rt qpcr western blot use detect mrna protein express low densiti lipoprotein receptor relat protein lrp catenin mg cell result show express level catenin mrna protein cell stress group signific increas p protein express level lrp signific decreas p express level lrp group great inhibit express level catenin signific upregul therefor fss stimul express lrp catenin osteoblast fluid shear stress promot osteoblast prolifer vitro wnt catenin signal pathway involv regul fluid shear stress promot osteoblast prolifer | D051176;D060492 | T123;T116;T192 |
36,262,982 | predict scar myometrium thick previous cesarean scar defect use three dimension vagin ultrasound research aim explor relat factor scar myometri thick scar diverticulum format predict occurr uterin diverticula patient cesarean section select research object accord three dimension vagin ultrasound echo diagnost criteria uterin diverticulum research object divid diverticulum group control group case group data age number cesarean section endometri thick uterin posit diverticulum size collect relationship uterin diverticulum compar analyz result show signific differ menstrual day cesarean section time uterin posit two group p height width depth posterior uterin diverticula scar diverticulum group greater anterior uterin height width depth respect residu myometrium thick posterior posit uterus anterior posit uterus differ statist signific p multivari analysi show frequenc cesarean section time time uterin posit abnorm menstruat independ risk factor scar diverticulum group p conclus menstrual abnorm number cesarean section time twice posit uterus independ risk factor format uterin scar diverticula deeper diverticula like menstrual abnorm prone diverticulum patient posterior uterus deeper diverticula patient dissect | D002921;D004240 | T047;T046;T190 |
36,262,981 | profound effect pulmonari surfact treatment preterm infant respiratori distress syndrom inherit diseas caus dysfunct pulmonari surfact metabol surfact dysfunct recent consid under caus neonat pediatr respiratori diseas respiratori distress syndrom prematur infant common respiratori diseas pediatr caus underdevelop lung infant lack activ substanc surfac alveoli lead insuffici lung function lead difficulti breath increas heart rate facial bruis neonat respiratori distress syndrom danger diseas high mortal rate great threat children live health therefor enough attent treatment caus clinic practic natur pulmonari surfact ps achiev posit effect treatment neonat respiratori distress syndrom rds reduc neonat mortal applic mechan ventil occurr late complic explor role pulmonari surfact treatment neonat respiratori distress syndrom analyz best time use ps prevent rds paper select prematur infant rds receiv neonat depart hospit provinc march octob compar efficaci pulmonari surfact ps preterm infant respiratori distress syndrom rds experi found averag mechan ventil time oxygen therapi time earli group shorter averag mechan ventil time oxygen therapi time late group demonstr earli administr pulmonari surfact ps therapi great help improv respiratori distress syndrom prematur infant | D011663;D012127 | T123;T047;T121;T109 |
36,262,980 | express hnrnp ab benign malign lung lesion earli diagnosi valu nsclc lung cancer occurr develop differ stage exist differ biolog behavior chang paper studi express heterogen nuclear ribonucleoprotein hnrnp ab benign malign lung lesion earli diagnosi valu nonsmal cell lung cancer nsclc aim provid refer earli diagnosi therapi nsclc lung surgeri specimen select januari march case receiv radiotherapi chemotherapi surgeri includ suffer benign lung lesion contrast set hnrnp ab express measur comparison experiment result show lung cancer suffer posit express hnrnp ab malign lesion tissu notori higher benign lesion tissu hnrnp ab differ express differ differenti differ stage | D002289;D034481;D008175 | T123;T191;T116 |
36,262,979 | applic research humanist care situat integr nurs schizophrenia recoveri period formul correspond nurs humanist care measur accord need patient evalu intervent effect patient provid refer nurs staff better provid nurs humanist care patient schizophrenia convalesc | D012559 | T048 |
36,262,977 | lagerstroemia speciosa amelior blood pressur lname induc hypertens experiment rat nocgmp oxid stress modul cardiovascular diseas primari reason chronic heart diseas mortal worldwid hypertens htn utmost domin risk factor evolut sever diseas herbal medicin tradit medicin herb extract wide util treat monitor htn herbal compon shown help relax arteri lower oxid stress current studi assess probabl role herbal plant extract lagerstroemia speciosa ls lname induc htn rat lname mg ml drinkabl water given rat five week signific upsurg lname treat hypertens rat blood pressur bp treatment ls amelior blood pressur ls also improv bodi weight reduc heart weight heart hypertrophi nocgmp concentr lower along substanti upsurg level glutathion declin mda level ls extract also reduc inflammatori cytokin marker system circul conclus thus extract ls treatment effici allevi bp oxid stress marker inflamm improv nocgmp concentr lname induc htn rat | D031563;D006973;D010946 | T047;T002 |
36,262,976 | signific edaravon combin emot manag model promot recoveri process improv negat psycholog patient type diabet mellitus combin stroke eighti one patient tdm combin cs attend hospit receiv rehabilit treatment march may enrol prospect nonrandom control analysi among patient receiv eda combin emot manag model regard observ group og receiv eda combin convent care seen control group cg clinic efficaci glycem function two group compar score activ daili live adl pittsburgh sleep qualiti index psqi self assess scale anxieti depress sas sds investig treatment time discharg patient satisfact care count within six month prognosi tdm self manag behavior cs self manag behavior score survey conduct | D003924;D020521 | T047 |
36,262,975 | emerg role dendrit cell intervent treatment inflammatori bowel diseas dendrit cell dcs import antigen present cell pivot initi effect adapt immun respons induc immun toler maintain immun homeostasi inflammatori bowel diseas ibd includ crohn diseas ulcer coliti chronic intestin inflammatori autoimmun disord dcs particip ibd pathogenesi review aim briefli discuss role dcs ibd relationship highlight promin role cell treatment disord | D015212;D003424;D003093 | T047 |
36,262,974 | antioxid anticanc potenti oliv sesam mixtur dimethylhydrazin induc colorect cancer wistar rat cancer one lead caus death worldwid natur agent shown promis fight thus present studi tri evalu heal potenti equal combin oliv sesam extract mos colorect cancer lesion induc dimethylhydrazin dmh male rat also compar anticarcinogen potenti mos vitamin e therefor mixtur equal oliv sesam extract mos use main treatment alongsid vitamin e parallel treatment studi examin red blood cell rbc white blood cell wbc level biochem indic lactat dehydrogenas ldh c reactiv protein crp total protein tp creatin kinas cpk albumin colon tissu patholog well level protein express adenomat polyposi coli apc prolifer cell nuclear antigen pcna carcinoembryon antigen cea platelet deriv growth factor pdgf also tissu stress marker includ total antioxid capac tac malondialdehyd mda superoxid dismutas sod analyz overal result repres signific reduct congest mitot index inflamm cell destruct mos group compar dmh group term oxid stress level signific increas observ dmh group comparison dmh mos group p mos signific increas tac level p furthermor dmhmos expos group exhibit signific lower express pcna cea pdgf protein dmh group overal mos show effect prevent dmh induc colon lesion mixtur strong antioxid agent clinic appli prevent treat colorect cancer effect higher vitamin e | D031658;D031685;D004111;D015179 | T121;T109;T168;T191;T002 |
36,262,973 | effect veget wast growth perform hematolog broiler chick veget wast spinach potato cauliflow rich natur sourc nutrient potenti good suppli miner essenti amino acid antioxid bird relat cost low easili access easili process pose littl risk ill aim present studi evalu effect veget wast vw feed supplement growth perform hematolog broiler chick purpos total day old vaccin chick acquir commerci hatcheri multan acclim three week day basal starter feed day old chick uniform bodi weight alloc accord crd complet random design four dietari treatment three replic contain chick pen dietari treatment chick feed basal feed bf supplement feed veget wast vw spinach potato cauliflow purpos dietari treatment includ control treatment bf vw dietari treatment bf vw bf vw bf vw bodi weight feed intak food convers ratio fcr mortal check week daili basi hematolog analysi st experiment week day old chick last th experiment week day old chick sampl blood gather wing vein two bird treatment random way end five week day bird uniform averag bodi weight select per treatment three replic birdrepl manual slaughter accord halal method analyz weight intern bodi organ broiler physic statist analysi anova signific effect p feed intak fcr among dietari treatment averag bodi weight bwg higher treatment p dietari treatment control treatment blood constitu studi show broiler control treatment dietari treatment fed differ dose signific p differ week w show higher valu blood constitu p week w carcass yield chick fed differ dose show signific differ p among dietari treatment vw inclus posit effect blood constitu carcass yield broiler chick signific p differ among treatment | D002645;D006405 | T091;T012 |
36,262,972 | integr analysi reveal nine tp pathway relat lncrna prognost signatur endometri cancer tp mutat common mutat gene uterin corpus endometri carcinoma ucec tp signal pathway play essenti role tumorigenesi progress immun infiltr ucec aim discov tp pathway relat lncrnas ucec materi method ucec patient transcript profil enrol studi first investig differenti status tp signal pathway tumor normal tissu gsea analysi identifi tp pathway relat lncrnas accord establish nine tp pathway relat lncrna signatur train set verifi signatur test set besid interact network construct immun infiltr drug respons cisplatin paclitaxel mutat atlas investig final perform subgroup analysi check univers signatur | D062085;D016889;D018269 | T123;T191;T114 |
36,262,971 | intradisc autolog platelet rich plasma inject discogen low back pain clinic trial platelet rich plasma prp contain high concentr growth factor cytokin may promot heal tissu format exert anti inflammatori effect prp shown improv intervertebr disc degener vivo vitro studi aim evalu effect autolog prp discogen low back pain dlbp week postinject patient receiv singl intradisc inject | D017116;D053657 | T184;T047;T031 |
36,262,970 | chang respiratori pathogen covid pandem studi aim investig pattern chang occur respiratori pathogen outbreak covid type viral pneumonia pandem declar march result analyz gender age identifi associ person hygien prevent infect respiratori pathogen | D000086382 | T047;T067 |
36,262,969 | prp person blood reliev joint fluid induc synovi injuri nf b pathway mitochondri apoptosi human synovi fibroblast cell platelet rich plasma prp therapi new kind biolog therapi retun plasma concentr patient bodi treatment osteoarthr diseas present research aims confirm treatment effect prp osteoarthr injuri elucid potenti mechan via construct kind cellular injuri model human synovi fibroblast cell hsf cell induc synovi fluid osteoarthr patient | D053657;D010003 | T047;T031 |
36,262,968 | compar effect rhus coriaria triamcinolon patient recurr aphthous stomat singl blind random control clinic trial recurr aphthous stomat ras common oral lesion unknown etiolog sever treatment strategi introduc treatment ras regard therapeut effect rhus coriaria one potenti treatment recent caught attent sinc clinic efficaci rhus coriaria examin adequ studi aim evalu therapeut effect rhus coriaria among patient ras | D029045;D013281 | T047;T002 |
36,262,967 | elev circ could acceler cell prolifer metastasi via mir ptwist axi hepatocellular carcinoma hepatocellular carcinoma hcc malign cancer lead mortal worldwid circ circrna play import role various kind tumor potenti function circ hcc remain unclear studi result microarray real time pcr rt pcr show obvious elev human hcc tumor tissu hcc cell line inhibit circ restrain cell prolifer migrat vitro furthermor mir p decreas tumor sampl indic target circ moreov twist establish elev hcc tissu identifi direct target mir p final found knockdown mir p could revers circ inhibit effect hcc cell conclus studi demonstr circ contribut promot hepatocellular carcinoma cell prolifer metastasi downregul mir p express elev twist express might provid new vision hcc patient | D006528;D008113;D035683 | T123;T191;T114 |
36,262,966 | correl igh cdr immun repertoir divers test peripher blood neuromyel spectrum diseas neuroretin spectrum disord nmosd general regard acut subacut inflammatori demyelin diseas central nervous system main involv optic nerv spinal cord mediat humor immun address question work establish immunom librari heavi chain complementar determin ghi cdr peripher blood lymphocyt b cell receptor librari establish patient spectrum neurosyphili retin disord six nmosd patient six healthi volunt recruit nmosd group divid earli onset group stabl group accord treatment condit igh cdr gene fragment cultur vitro amplifi multiplex pcr technolog gene sequenc second generat high throughput sequenc technolog statist analysi carri method without refer quantiti type divers igh cdr peripher blood b lymphocyt nmosd patient signific lower normal group p variat igh cdr sequenc initi stage treatment higher stabl stage p replic frequenc characterist gene cassiclgsgcggyyygmdvw signific increas patient initi stage nmosd treatment p conclus gene express gene express analysi nmosd patient could accur judg condit nmosd patient evalu efficaci provid new molecular target new theoret basi clinic applic | D022801;D009471 | T129;T047;T116 |
36,262,936 | innov explor comput aid new media translat cours teach mode ecolog environ order analyz innov comput new media aid translat cours teach mode ecolog environ paper introduc corptran system analyz practic effect comput aid translat system appli cours teach verifi role system comput aid translat cours teach play import role improv student translat abil time start develop trend new media environ corptran system use innov teach mode comput aid translat cours teach ecolog comprehens new media translat curriculum consist interact ecolog subject teach ecolog environ teach effort teacher student high qualiti comput aid translat cours contribut cultiv compound translat talent innov teach mode need realiz system better meet requir improv teach level translat cours | D003479;D013334 | T065;T081;T170;T098 |
36,262,935 | juvenil delinqu perspect social social control recent year crime rate minor countri risen steadili lay hidden danger harmoni order develop countri societi healthi growth teenag relat harmoni famili futur nation also destini countri therefor order ensur healthi growth young peopl prevent juvenil delinqu start caus juvenil delinqu identifi core issu better studi juvenil delinqu school famili strengthen educ minor guid develop posit term law strengthen supervis minor prevent break law | D007604 | T055 |
36,262,934 | analysi relationship nation imag build intern communic abil perspect ecolog media environ gradual expans china polit econom militari strength rapid rise china becom global recogn fact present although china intern imag world second largest economi militari power polit power increas accept global communiti china imag construct import part nation soft power still face mani problem chapter focus defin basic concept intern public china soft power china imag construct context new media integr analyz intern develop trend intern public import function limit foreign public establish china imag construct analyz ecolog environ media integr develop consid great unfair environ conflict communic valu conduc establish china urban imag articl focus use global public valu establish china nation imag put forward correspond countermeasur | D004777;D003142 | T082;T067;T080;T170;T054;T097 |
36,262,875 | pomalidomid treatment relapsedrefractori multipl myeloma patient real world data hungari pomalidomid third generat immunomodulatori drug treatment refractori relaps multipl myeloma patient aim investig efficaci safeti pomalidomid therapi real world set eighti six hungarian patient includ receiv pomalidomid alkyl agent pomalidomid combin proteasom inhibitor patient show respons treatment complet good partial remiss partial remiss median durat follow month median progress free surviv pfs month median overal surviv os month whole cohort patient earli stage diseas r iss better surviv result stage myeloma p neither number prior treatment line lenalidomid refractori signific impact pfs pfs found similar cohort patient impair renal function cohort without kidney involv studi eight mortal infect two fatal bleed complic occur howev mild hematolog gastrointestin toxic identifi frequent advers event result investig confirm pomalidomid effect treatment option relapsedrefractori mm besid safeti profil satisfactori subject normal impair renal function | D009101 | T191 |
36,262,874 | identif drug diseas associ use random walk restart method supervis learn drug diseas correl play import role reveal mechan diseas find new indic avail drug drug reposit varieti comput approach propos find drug diseas correl achiev good perform howev method use varieti network inform integr network rare use addit role known drug diseas associ data fulli play work design combin algorithm random walk supervis learn find drug diseas correl use integr network updat model select gene set start random walk base known drug diseas correl data experiment result show propos method effect find correl drug diseas predict accuraci found pair drug diseas relationship yet report pharmacodynam effect parkinson diseas also found key linkag parkinson diseas phenylhexol drug treatment parkinson diseas synuclein tau protein provid use explor effect treatment parkinson diseas | D019295;D010300 | T047;T091 |
36,262,873 | novel methylcytosin immun relat prognost signatur potenti marker idiopath pulmonari fibrosi idiopath pulmonari fibrosi ipf common high lethal pulmonari interstiti lung diseas current studi aim investig reliabl marker suitabl treatment identif ipf studi construct first methylcytosin mc immun relat prognost signatur mcps base coexpress gene mc regulatori gene immun relat gene mcps establish use train cohort n verifi use test n valid n cohort area curv auc valu util evalu accuraci mcps predict surviv ipf patient kaplan meier curv cox regress analys use assess prognost effect mcps auc util evalu reliabl mcps distinguish ipf patient healthi individu term result mcps could predict one three five year surviv rate ipf patient high accuraci auc fact mcps independ indic poor prognosi ipf patient hazard ratio p also distinguish ipf patient healthi individu auc also mcps may affect immun respons inflammatori respons posit associ infiltr level activ mast cell p sum current studi establish novel mcps ipf reveal role mcps reliabl marker predict prognosi diseas status ipf patient | D054990 | T047 |
36,262,872 | mir p promot radiotherapi sensit hepatocellular carcinoma regul cell cycl via mcl relationship tumor suppressor gene mir p radiotherapi hepatocellular carcinoma hcc remain unclear studi intend illustr molecular mechan mir p regul radiotherapi sensit hcc | D006528;D035683;D008113 | T123;T191;T114 |
36,262,871 | dynam incis nasal endoscop low temperatur plasma radiofrequ ablat nasal invert papilloma analysi differ efficaci destruct effect immun function nip patient n admit januari march select group follow accord random number tabl method dissect group treat dynam system surgeri nasal endoscop ablat group treat ltpra clinic curat effect two procedur compar relat index oper time ot intraop blood loss ibl length stay los postop advers reaction ar count addit fast venous blood sampl collect treatment well day treatment detect inflammatori factor if c reactiv protein crp interleukin il tumor necrosi factor tnf lymphocyt subset cd cd cd final patient receiv one year follow compar differ prognost surviv rate diseas recurr rate group | D018308;D017115 | T061;T191 |
36,262,870 | comparison effect three differ surgic procedur ankl joint function rehabilit patient heppl v talus osteochondr injuri discuss compar effect three differ surgic procedur ankl function rehabilit patient heppl v talus osteochondr injuri | D013628;D002358 | T023;T024 |
36,262,869 | efficaci cold atmospher plasma therapi chronic wound updat systemat review meta analysi rcts previous meta analysi reveal cold atmospher plasma cap might clinic benefici chronic wound howev sever new random control trial rcts report cap effect treatment option acceler wound heal chronic wound purpos review incorpor new result evalu efficaci cap chronic wound | D058626;D007036 | T061;T104 |
36,262,868 | research ct lung segment method preschool children base tradit imag process resunet lung segment use comput tomographi ct imag import diagnos various lung diseas current lung segment method develop assess ct imag preschool children may differ adult due presenc artifact caus shake children loss local lung area due failur hold breath smaller ct chest area compar adult solv uniqu problem studi develop automat lung segment method combin tradit imag method resunet use ct imag children age year first ct imag crop zoom ecolog oper concentr segment task chest area resunet model use improv loss lung segment case base connect domain oper perform filter segment result improv segment accuraci propos method demonstr promis segment result test set case averag accuraci dice precis recal respect achiev best perform relat six model studi show propos method achiev good segment result ct preschool children lay good foundat diagnosi children lung diseas | D007091;D008171 | T047;T066 |
36,262,827 | deplet revers hepatocellular carcinoma induc ctl er stress depend perk chop signal pathway report investig hepatoma cell caus downregul cytotox lymphocyt ctl function tea polyphenol tps revers downregul ctl function | D006528;D008113 | T191 |
36,262,769 | non select alpha blocker provid stabl intraop hemodynam control compar select alpha blocker patient pheochromocytoma paraganglioma singl center retrospect cohort studi propens score match analysi china alpha adrenerg blocker use preoper prepar patient pheochromocytoma paraganglioma ppgls despit controversi periop hemodynam aim determin whether select non select adrenerg blocker provid better efficaci patient intraop hemodynam | D010673;D000310;D010235 | T191 |
36,262,747 | auditori process neuron influenc song evalu strength mate prefer femal songbird anim use varieti complex signal mechan convey array inform detect conspecif heterospecif receiv signal perceiv inform use direct subsequ action thus communic occur sender receiv vocal communic signal power model investig neural basi sensori percept action initi underli decis make studi investig femal songbird perceiv qualiti acoust signal song perform male use inform express prefer one song among mani possibl altern use behavior measur song prefer lesion induc alter activ auditori process area caudal nidopallium nc previous describ interconnect auditori area downstream reward pathway find reveal inactiv nc chang femal abil willing perform behavior indic mate choic chang abil identifi song individu male howev lesion nc induc decreas strength song prefer specif male other decreas result complet elimin prefer femal prefer specif male still evid strong express lesion nc taken togeth data indic nc play role femal strength prefer song evalu mate choic activ nc import facet mate choic | D020308;D001303 | T023;T029;T012 |
36,262,713 | effect euthanasia educ view nurs student nurs play import role healthcar team close involv daili care patient sometim involv care termin patient may thus confront difficult end life decis euthanasia therefor import determin view euthanasia nurs student work health care prepar situat profession life studi aim evalu effect euthanasia educ nurs student opinion | D013338;D005065 | T058;T097 |
36,262,712 | catastroph health expenditur impoverish non communic diseas comparison privat public health facil ekiti state southwest nigeria catastroph health expenditur impoverish outcom poor financ mechan littl known preval predictor outcom among non communic diseas patient privat public health facil | D005102;D000073296 | T081;T047 |
36,262,711 | barrier challeng self care among older adult knee osteoarthr qualit studi knee osteoarthr koa chronic diseas caus disabl older adult self care effect strategi koa manag older adult clinician shown increas interest regard challeng self care activ patient present studi aim explor percept older adult patient koa regard barrier challeng face self care manag | D020370 | T047 |
36,262,710 | assess risk factor advanc open angl glaucoma present among patient visit jimma univers medic center jimma ethiopia glaucoma predomin caus irrevers blind particular late present purpos studi identifi risk factor associ late present jimma univers medic center | D005902;D005901 | T047 |
36,262,709 | knowledg practic glasgow coma scale assess among nurs work adult intens care unit feder public hospit addi ababa ethiopia cross section studi glasgow coma scale depend object neurolog assess instrument use determin record patient level conscious therefor knowledg practic factor affect glasgow coma scale evalu among nurs work adult intens care unit feder administ hospit addi ababa ethiopia investig | D007722;D006768 | T053;T073;T093 |
36,262,708 | trend challeng access essenti medicin ethiopia contribut local pharmaceut product decad ago unit nation declar access essenti medicin key element univers human right accord member state strive address issu strateg polici program strengthen local pharmaceut product pivot strategi adopt mani develop countri includ ethiopia govern ethiopia identifi local pharmaceut product key industri sector implement ten year strateg plan improv capabl attract invest support need local product could satisfi nation demand typic limit portfolio medicin convent dosag form increas preval chronic diseas accentu need sustain suppli reduc relianc import increas access essenti medicin full understand structur constraint complex ethiopian pharmaceut market structur vital direct effect polici target impact invest exploit opportun leapfrog henc purpos review assess trend challeng access essenti medicin local pharmaceut product ethiopia literatur search major databas review polici document perform report relev sector institut made extract inform review | D018954 | T121 |
36,262,707 | comparison topic oxygen vacuum assist closur wound heal low resourc set aim pilot studi obtain preliminari result compar topic oxygen therapi tot vacuum assist closur vac term abil acceler wound heal | D054843 | T061;T074 |
36,262,706 | antiepilept drug adher associ factor among epilepsi patient follow up amanuel mental special hospit ethiopia medic adher fundament determin effect treatment howev peopl epilepsi poor complianc treatment chronic natur diseas limit studi conduct address antiepilept medic adher africa includ ethiopia thus aim studi assess antiepilept drug adher asoci factor among patient epilepsi attend outpati depart amanuel mental special hospit | D000927;D004827 | T033;T121;T047 |
36,262,705 | ureteroscopi outcom determin resourc limit set ureteroscopi major diagnost therapeut techniqu lesion uret intraren collect system | D018666;D014514 | T061;T058;T047 |
36,262,704 | assess health literaci health promot behavior among urban adult popul main criteria health determin health promot behavior hpbs health literaci hl studi aim assess hl hpbs among urban popul adult | D057220 | T041 |
36,262,703 | electroencephalograph find antiepilept drug risk factor individu refer tertiari care hospit ethiopia littl known characterist electroencephalogram eeg find epilept patient ethiopia object studi character eeg pattern indic antiepilept drug a epilepsi risk factor | D015658;D004827;D001932;D006259 | T033;T047;T191;T037 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.